Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $43.25.
ARWR has been the topic of a number of recent research reports. B. Riley reissued a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Thursday, August 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th.
Read Our Latest Research Report on ARWR
Arrowhead Pharmaceuticals Price Performance
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 152.95%. Arrowhead Pharmaceuticals’s revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.96) earnings per share. On average, equities analysts anticipate that Arrowhead Pharmaceuticals will post -4.31 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Arrowhead Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of ARWR. Fifth Third Bancorp increased its stake in Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 354 shares in the last quarter. Arizona State Retirement System increased its position in shares of Arrowhead Pharmaceuticals by 2.4% in the 2nd quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after acquiring an additional 821 shares during the period. Securian Asset Management Inc. raised its stake in Arrowhead Pharmaceuticals by 12.5% in the 1st quarter. Securian Asset Management Inc. now owns 10,100 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 1,121 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in Arrowhead Pharmaceuticals by 3.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock worth $901,000 after acquiring an additional 1,250 shares during the period. Finally, Neo Ivy Capital Management purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $41,000. 62.61% of the stock is owned by hedge funds and other institutional investors.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Further Reading
- Five stocks we like better than Arrowhead Pharmaceuticals
- Stock Market Sectors: What Are They and How Many Are There?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- What Are Dividend Achievers? An Introduction
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Overbought Stocks Explained: Should You Trade Them?
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.